#Sweden #Gothenburg #Cancer Research #Assar Gabrielsson Prize #Ketan Thombare

Celebrating the 2026 Assar Gabrielsson Prize Winners

On May 6, 2026, the Assar Gabrielsson Foundation honored the remarkable achievements of researchers in the field of cancer with its prestigious annual prizes. This year, the foundation, which has a rich history dating back to 1962, awarded Ketan Thombare for his groundbreaking work in basic science and Louise Carstam along with Ella Äng Eklund for their contributions in clinical research.

Ketan Thombare's Contributions to Basic Science

Ketan Thombare received the award for his innovative research focusing on the intricate processes of RNA modifications and their roles in cancer biology, specifically in high-risk neuroblastoma. This type of cancer predominantly affects children and has been notoriously difficult to treat. Thombare's findings shed light on how modifications to RNA can influence the identity and behavior of tumor cells, thereby providing critical insights into potential therapeutic strategies. According to Eva Forssell-Aronsson, a professor at the University of Gothenburg and an executive member of the Assar Gabrielsson Foundation, Thombare’s research is pivotal for understanding the underlying RNA-mediated mechanisms that distinguish aggressive types of cancer.

Advancements in Clinical Research

Louise Carstam's Work

Louise Carstam was recognized in the clinical research category for her focused studies on diffuse low-grade gliomas, a brain tumor type often characterized by the initial presentation of epileptic seizures in young adults who otherwise show no symptoms. Her research aims to improve treatment protocols by evaluating when early intervention is necessary versus when it is more appropriate to adopt a watchful waiting approach. This work is essential as it can drastically impact the quality of life and long-term outcomes for patients.

Ella Äng Eklund's Clinical Insights

Alongside Carstam, Ella Äng Eklund was awarded for her innovative approaches in identifying prognostic and predictive biomarkers that guide treatment selection. Her work bridges laboratory research and clinical practices, aiming to translate laboratory discoveries directly into benefits for patients. Eklund, who recently defended her thesis focusing on KRAS-mutated non-small cell lung cancer, brings a promising perspective to personalized treatment strategies, highlighting the importance of individualized patient care in oncology.

A Legacy of Support for Cancer Research

Founded by one of Volvo's original creators, the Assar Gabrielsson Foundation has been instrumental in fostering promising cancer research endeavors that might not be supported by larger funding entities. The foundation’s initiative not only provides financial support, with each prize winner receiving SEK 100,000, but also encourages innovative research that can lead to significant advancements in cancer therapies.

In recent years, cancer research has made substantial strides; however, projects that hold promise but lack sufficient funding often struggle to get off the ground. The Assar Gabrielsson Foundation's ongoing commitment to supporting such research reinforces the need for sustainable funding in the scientific community.

Looking Ahead

As these awardees embark on their next phases of research, their findings promise to nurture advancements in understanding and treating cancer. With significant financial backing from the foundation, the winners of the Assar Gabrielsson Prize are poised to make impactful contributions not only to science but also to the lives of many affected by cancer.

For more information on the recipients and their groundbreaking research, as well as updates from the Volvo Group, visit Volvo Group's official website.